<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00401440</url>
  </required_header>
  <id_info>
    <org_study_id>3-Chaudhuri</org_study_id>
    <nct_id>NCT00401440</nct_id>
  </id_info>
  <brief_title>Comparison of Two Regimens of Misoprostol for Second Trimester Medical Termination of Pregnancy</brief_title>
  <official_title>Comparison of Twq Different Regimen of Vaginal Misoprostol for Nid Trimester MTP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nilratan Sircar Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nilratan Sircar Medical College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of the study is that the induction abortion interval time will be&#xD;
      significantly shorter in the group receiving vaginal misoprostol every six hours in&#xD;
      comparison to the group who are receiving vaginal misoprostol every twelve hours.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      Misoprostol, a prostaglandin analogue, is principally used to prevent peptic ulcer disease&#xD;
      induced by nonsteroidal anti-inflammatory agents .It has been shown to induce second&#xD;
      trimester abortion .However , the optimal regimen has not been determined .Studies have used&#xD;
      doses ranging 200- 800 microgram misoprostol at interval ranging from 3-12 hours.1,2,3,4,5 In&#xD;
      our previous study we have compared intravaginal misoprostol with extra amniotic ethacridine&#xD;
      lactate for second trimester MTP.6 In this study we have observed that misoprostol is highly&#xD;
      effective( success rate 95%) for second trimester MTP with minimal side effects .&amp;&#xD;
      intravaginal misoprostol results in significantly shorter induction abortion interval in&#xD;
      comparison to extra amniotic ethacridine lactate .Induction abortion interval in this study&#xD;
      for misoprostol was 15.5 hours and the dosage of misoprostol was 400 microgram vaginally&#xD;
      every 12 hours with a maximum of 4 doses .Success rate and induction abortion interval are&#xD;
      the major factors of clinical importance for second trimester MTP . Our aim is to establish a&#xD;
      dosage schedule of misoprostol which will result in high success rate in mid trimester MTP&#xD;
      with further shortening of induction abortion interval Our study hypothesis is that using 400&#xD;
      microgram of vaginal misoprostol at six hour interval will result in significant shortening&#xD;
      of induction abortion interval in comparison to 400 microgram vaginal misoprostol at 12 hour&#xD;
      interval.&#xD;
&#xD;
      Methods - A prospective randomized comparative clinical trial will be conducted over 200&#xD;
      women.&#xD;
&#xD;
      Women attending the hospital for mid trimester MTP i.e. 12-20 weeks of pregnancy will be&#xD;
      taken up for the study. Gestational age will be determined from LMP &amp; per abdominal findings.&#xD;
      Ultrasonography will be done in selected women where clinical finding is unreliable . All&#xD;
      women will be examined for vital parameters and routine hematological and urine examination&#xD;
      will be done. Randomization will be done using a table of random numbers .A written consent&#xD;
      for inclusion in the study will be taken from all patients who will be included in the study.&#xD;
&#xD;
      In one group women will receive 400 microgram vaginal misoprostol tablet at interval of 12&#xD;
      hours with a maximum of four doses.&#xD;
&#xD;
      In other group women will receive 400 microgram vaginal misoprostol tablet at an interval of&#xD;
      6 hours with a maximum of four doses.&#xD;
&#xD;
      Failure of procedure in both groups will be defined as failed expulsion of fetus at 48 hours&#xD;
      or as the occurrence of systemic adverse signs and symptoms severe enough to preclude the use&#xD;
      of additional drugs.&#xD;
&#xD;
      The patient's vital signs will be monitored every four hours and the occurrence of signs and&#xD;
      symptoms, such as fever, pain, vomiting, and diarrhea will be recorded. After expulsion of&#xD;
      the fetus and placenta, check curettage will be done in every case. Completeness of abortion&#xD;
      will be defined as expulsion of both placenta and fetus without operative assistance. The&#xD;
      induction abortion interval will be defined as time from administration of 1st dose of&#xD;
      Misoprostol to abortion of fetus. Hemorrhage will be defined as an estimated blood loss&#xD;
      exceeding 500 ml or need to blood transfusion. Fever will be defined as rise of temperature&#xD;
      100.4Ëš F or more occurring 24 hours or more after pregnancy termination.&#xD;
&#xD;
      The following parameters will be studied (1) Induction abortion interval (2) Completeness of&#xD;
      procedure (3) Failure of abortion (4) side effects (5) cost per procedure.&#xD;
&#xD;
      Statistical analysis will be carried out with Epi Info statistical software.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>induction abortion interval</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success rate</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete expulsion of products of conception</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">185</enrollment>
  <condition>Induced Abortion</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 microgram vaginal misoprostol tablet will be applied every 6 hours with a maximum of 4 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 microgram vaginal misoprostol tablet will be applied every 12 hours with a maximum of 4 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>400 microgram vaginal misoprostol tablet will be applied every 6 hours with a maximum of 4 doses</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>400 microgram vaginal misoprostol tablet will be applied every 12 hours with a maximum of 4 doses</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women fulfilling indications of Medical Termination Of Pregnancy Act of India&#xD;
&#xD;
          -  12-20 weeks of pregnancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with previous uterine surgery&#xD;
&#xD;
          -  Contraindication of misoprostol use&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Snehamay Chaudhuri, MBBS,MD,DNB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nilratan Sircar Medical College , 138,AJC Bose Road , Kolkata,700014,West Bengal , India.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Gynae &amp; Obstetrics, Nilratan Sircar Medical College , Kolkata</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://medind.nic.in/jaq/t06/i6/jaqt06i6p518.pdf</url>
    <description>A comparison of intra vaginal misoprostol with extra amniotic ethacridine lactate for second trimester MTP, J Obstet Gynecol India .56.6:2006.518-521</description>
  </link>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>November 16, 2006</study_first_submitted>
  <study_first_submitted_qc>November 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2006</study_first_posted>
  <last_update_submitted>March 11, 2010</last_update_submitted>
  <last_update_submitted_qc>March 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chairperson , I Ethical Committee &amp; Principal</name_title>
    <organization>Nilratan Sircar Medical College , Kolkata</organization>
  </responsible_party>
  <keyword>Medical termination of pregnancy</keyword>
  <keyword>Induction of abortion</keyword>
  <keyword>Misoprostol</keyword>
  <keyword>MTP in second trimester</keyword>
  <keyword>400 microgram vaginal misoprostol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

